Mat Angelos

16 posts

Mat Angelos banner
Mat Angelos

Mat Angelos

@Mat_Angelos

Leukemia & Cell Therapy/Transplant faculty @CUHematology | Physician-scientist | Previously @PennCancer @PennIMResidents @UMNMSTP @DukeU

Denver, CO Katılım Şubat 2018
181 Takip Edilen122 Takipçiler
Mat Angelos
Mat Angelos@Mat_Angelos·
Pleased to share our manuscript featured on the cover of @BloodPortfolio on CD2-targeting CART and CD2 signaling in CART. Great to work with @AlbertoCarturan @MarcoRuella and all to share this story - expanding targets for aggressive T cell neoplasms. sciencedirect.com/science/articl…
Blood Journals Portfolio@BloodPortfolio

New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/issue/14…

English
1
1
4
424
Mat Angelos
Mat Angelos@Mat_Angelos·
Pleased to share our results in @NatureMedicine using CAR-macrophages against solid tumors in this FIH trial. CAR-M were safe and showed tumor immunomodulatory activity in heavily pretreated pts. Great to work with @KReissMD and all authors! @PennCancer
English
1
2
2
610
Mat Angelos retweetledi
Alberto Carturan
Alberto Carturan@AlbertoCarturan·
Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor @MarcoRuella and the @RuellaLab for their invaluable support. Excited to delve deeper into this approach!
Alberto Carturan tweet media
English
0
6
13
1K
Mat Angelos retweetledi
Marco Ruella
Marco Ruella@MarcoRuella·
@Mat_Angelos from our @RuellaLab presenting for the for the first time a novem CD2 deleted CART2 for T-ALL: High preclinical efficacy against primary leukemias #ASH23 @PennMedicine
Marco Ruella tweet media
San Diego, CA 🇺🇸 English
0
3
8
597
Mat Angelos
Mat Angelos@Mat_Angelos·
Check out our phase 1 CAR-M study in progress at the Developmental Therapeutics session Sunday AM. Excited to meet you at 327b and discuss other new cell therapy work at #ASCO2022 @KReissMD
Penn Medicine MD@PennMDForum

🔬 Can macrophages be harnessed to #CARTherapy to fight solid tumors? @KReissMD presents on a first-in-human study of the anti-HER2 CAR macrophage CT-0508 in patients with #HER2 overexpressing solid tumors: spr.ly/6017znKjJ #ASCO22 #CARM

English
0
1
8
0
Mat Angelos
Mat Angelos@Mat_Angelos·
Check out our recent (open-access!) review on what's new in treating T-cell lymphomas. mdpi.com/1494870
English
0
0
2
0
Mat Angelos
Mat Angelos@Mat_Angelos·
Thanks @LizTraxler for the cupcakes today! They were a ‘blast!’
Mat Angelos tweet media
English
0
1
5
0
Mat Angelos
Mat Angelos@Mat_Angelos·
Feel like there should be a greater emphasis on understanding when/how to implement appropriate statistical methods and improve study designs than just simply lowering the significance threshold... The Proposal to Lower P Value Thresholds to .005 ja.ma/2HFzzye
English
0
0
0
0
Mat Angelos
Mat Angelos@Mat_Angelos·
Great approach for grad student training at Hopkins. Programming and bioinformatics work was some of the most creative and formative parts of my research; would be great to see this emphasized in more biological science programs. twitter.com/nature/status/…
Nature Portfolio@NaturePortfolio

Many doctoral curricula aim to produce narrowly focused researchers rather than critical thinkers. That can and must change, says Gundula Bosch go.nature.com/2Ew4qb9

English
0
0
0
0
Mat Angelos
Mat Angelos@Mat_Angelos·
Starting up my first Twitter page! Excited to use this as a platform to disseminate thought-provoking, evidence-based, and informative content. Hope to include a lot of science, medicine, medical education, STEM career development, and some other personal interests!
English
0
0
2
0

Keşfet

@BloodPortfolio @AlbertoCarturan @MarcoRuella @NatureMedicine @KReissMD @PennCancer @RuellaLab @_ruchipatel